Medications

Dabigatran doesn't beat aspirin for preventing recurrent stroke

(HealthDay)—Dabigatran is not superior to aspirin for preventing recurrent stroke in patients with recent history of embolic stroke of undetermined source, according to a study published in the May 16 issue of the New England ...

Autism spectrum disorders

Digital intervention ups socialization in children with autism

(HealthDay)—An artificial intelligence-driven wearable behavioral intervention, Superpower Glass, can improve social outcomes for children with autism spectrum disorder (ASD), according to a study published online March ...

Health

Notes reflecting financial considerations ID'd in ICU

(HealthDay)—Among patients in the intensive care unit (ICU), 4.2 percent of admissions have at least one note reflecting financial considerations, according to a study published online Nov. 2 in JAMA Network Open.

Health

Early readmissions more preventable than later ones

(HealthDay)—Early general medicine readmissions are more likely than late readmissions to be preventable with hospital-based interventions, according to a study published online May 1 in the Annals of Internal of Medicine.

Diseases, Conditions, Syndromes

Serlopitant found to be safe, effective for chronic pruritus

(HealthDay)—Serlopitant has potential as a therapy for the treatment of chronic pruritus, according to a study published in the May issue of the Journal of the American Academy of Dermatology.

Oncology & Cancer

PAs may have lower diagnostic accuracy for melanoma

(HealthDay)—Physician assistants (PAs) perform more skin biopsies per case of skin cancer diagnosed and diagnose fewer melanomas in situ than dermatologists, according to a study published online April 18 in JAMA Dermatology.

Cardiology

No higher cancer risk seen for heart failure patients

(HealthDay)—Heart failure is not associated with an increased risk of cancer, according to a study published in the April 10 issue of the Journal of the American College of Cardiology.

Pediatrics

Recombinant influenza vaccine found to be safe in children

(HealthDay)—The recombinant influenza vaccine (RIV4) is well tolerated in children aged 6 to 17 years, and it provides immunogenicity comparable to that of the inactivated vaccine, according to a study published online ...

page 7 from 33